Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of “Moderate Buy” by Analysts

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) have received a consensus rating of “Moderate Buy” from the twelve analysts that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $32.00.

A number of brokerages have issued reports on VRDN. Wedbush increased their price objective on shares of Viridian Therapeutics from $39.00 to $40.00 and gave the company an “outperform” rating in a report on Wednesday, February 28th. The Goldman Sachs Group assumed coverage on shares of Viridian Therapeutics in a report on Thursday, June 6th. They issued a “buy” rating and a $23.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and set a $30.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, June 11th. Oppenheimer cut their price objective on Viridian Therapeutics from $36.00 to $31.00 and set an “outperform” rating for the company in a research report on Thursday, May 9th. Finally, HC Wainwright decreased their target price on Viridian Therapeutics from $37.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, May 9th.

Viridian Therapeutics Stock Down 1.9 %

VRDN opened at $12.20 on Tuesday. The stock has a market cap of $778.60 million, a price-to-earnings ratio of -2.71 and a beta of 1.03. The company has a debt-to-equity ratio of 0.05, a quick ratio of 23.99 and a current ratio of 23.99. The firm’s fifty day moving average is $13.67 and its 200 day moving average is $17.35. Viridian Therapeutics has a fifty-two week low of $10.93 and a fifty-two week high of $27.50.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.28. The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.09 million. Viridian Therapeutics had a negative return on equity of 92.04% and a negative net margin of 75,737.85%. The business’s revenue was down 26.5% on a year-over-year basis. During the same period in the previous year, the business earned ($1.61) earnings per share. On average, sell-side analysts forecast that Viridian Therapeutics will post -3.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Viridian Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. RTW Investments LP bought a new stake in Viridian Therapeutics in the fourth quarter worth $13,195,000. Perceptive Advisors LLC boosted its stake in shares of Viridian Therapeutics by 71.1% during the 4th quarter. Perceptive Advisors LLC now owns 1,730,212 shares of the company’s stock worth $37,684,000 after purchasing an additional 719,007 shares during the period. Dark Forest Capital Management LP bought a new position in Viridian Therapeutics during the 3rd quarter valued at about $264,000. Schonfeld Strategic Advisors LLC grew its holdings in Viridian Therapeutics by 362.3% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 108,037 shares of the company’s stock valued at $1,657,000 after purchasing an additional 84,670 shares during the last quarter. Finally, StoneCrest Wealth Management Inc. purchased a new stake in Viridian Therapeutics in the 4th quarter worth about $605,000.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.